FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Early Alert on Baxter Volara Breathing Device Circuits

FDA issues an early alert regarding a potentially high-risk issue affecting certain patient circuits used with Baxter's Volara System.

Animal Drugs

FDA Authorizes 1st Generic Animal Drug for New World Screwworm

FDA authorizes Felix Pharmaceuticals generic nitenpyram tablets to treat New World screwworm infestations in dogs and cats.

latest-news-card-1
Human Drugs

FDA Issues 2nd Complete Response Letter on Acromegaly Drug

FDA sends a second complete response letter to Camurus regarding its NDA for Oclaiz (octreotide), an extended-release injection under review for the t...

latest-news-card-1
Human Drugs

Doctor, Staff Charged with Falsifying Trial Data

The Department of Justice says a federal grand jury has indicted the co-owner of Floridas Pine Care Research Center and two staff members on charges t...

latest-news-card-1
Human Drugs

Kidney Risk in OTC Weight Loss Drug Alli

FDA approves labeling changes for Haleons OTC weight loss drug alli to warn of the rare risk of kidney injury associated with its use.

latest-news-card-1
Human Drugs

Fewer But Longer Drug Shortages: USP Report

The United States Pharmacopoeia 2025 annual drug shortage report documents a reduction in the number of drug shortages but an increase in the time dur...

latest-news-card-1
Human Drugs

Require In Vivo BE Test for Tafinlar ANDA: Petition

A Windels Marx petition asks FDA not to approve any ANDA for dabrafenib mesylate using the 505(j)(2)(C) pathway that doesnt include in vivo bioequival...

latest-news-card-1
Human Drugs

Plausibility Mechanism Guidance Needs Clarifications: Article

A Health Affairs article discusses clarifications and revisions that it says are needed in an FDA draft guidance describing a plausible mechanism fram...

latest-news-card-1

Changes in HCEI Draft Guidance Noted

Three Akin Gump attorneys highlight some changes in a 2026 FDA draft guidance on communicating healthcare economic information from its 2018 final gui...

latest-news-card-1
Human Drugs

Comments Extended and Workshop Planned for Drug Repurposing

FDA extends the comment period by 30 days for its request for information on drug repurposing for unmet medical needs.